“Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis”. 2025. Open Access Indonesian Journal of Medical Reviews 5 (5): 607-26. https://doi.org/10.37275/oaijmr.v5i5.780.